ZS Pharma prices IPO at $18, above the range

By
A A A

ZS Pharma, a late-stage biotech developing a treatment for excess potassium (hyperkalemia), raised $107 million by offering 5.9 million shares (vs. 5 million originally planned) at $18, above the $15 to $17 range. ZS Pharma will list on the NASDAQ under the symbol ZSPH. J.P. Morgan and Credit Suisse acted as joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: ZSPH

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Lies Retailers Tell
Lies Retailers Tell                 

Stocks

Referenced

100%

Most Active by Volume

36,788,916
  • $42.56 ▲ 5.92%
23,641,549
  • $103.46 ▲ 0.97%
21,508,305
  • $8.19 ▲ 0.24%
19,149,368
  • $16.64 ▲ 0.24%
14,780,480
  • $79.53 ▲ 1.07%
13,091,675
  • $12.47 ▲ 3.66%
13,026,637
  • $97.24 ▲ 0.38%
11,849,199
  • $28.4599 ▲ 0.64%
As of 10/22/2014, 11:12 AM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com